Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical experience with famciclovir against hepatitis B virus.

Intervirology - 1 Jan 1997

Bartholomeusz A, Groenen L C, Locarnini S A

Abstract excerpt

Famciclovir (FCV, the oral form of penciclovir, PCV) is a potent antiviral agent of hepatitis B virus (HBV) and is currently in phase III clinical trials. In this review, we examine the outcome of FCV treatment in preventing recurrent HBV in patients post transplantation. Resistance to FCV has now been documented in this setting, in which reduced sensitivity to FCV was associated with mutations upstream from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, Viral
Share to Amino Acid Sequence
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B virus

Share to Models, Molecular

Share to Molecular Sequence Data

Share to Mutation

Source

Identifiers

PMID: 9675638
DOI: 10.1159/000150566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Clinical experience with famciclovir against hepatitis B virus.PMID 9675638Read ↗

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.Semantic proximity Read ↗

Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges.Semantic proximity Read ↗

Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant.Semantic proximity Read ↗

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.Semantic proximity Read ↗

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.Semantic proximity Read ↗

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.Semantic proximity Read ↗

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.Semantic proximity Read ↗

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semantic proximity Read ↗

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.Semantic proximity Read ↗

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.Semantic proximity Read ↗

Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.